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Abstract
Germline mutations in BUB1 and BUB3 have been reported to increase the risk of developing colorectal cancer (CRC) at
young age, in presence of variegated aneuploidy and reminiscent dysmorphic traits of mosaic variegated aneuploidy
syndrome. We performed a mutational analysis of BUB1 and BUB3 in 456 uncharacterized mismatch repair-proficient
hereditary non-polyposis CRC families and 88 polyposis cases. Four novel or rare germline variants, one splice-site and
three missense, were identified in four families. Neither variegated aneuploidy nor dysmorphic traits were observed in
carriers. Evident functional effects in the heterozygous form were observed for c.1965-1G>A, but not for c.2296G>A
(p.E766K), in spite of the positive co-segregation in the family. BUB1 c.2473C>T (p.P825S) and BUB3 c.77C>T (p.T26I)
remained as variants of uncertain significance. As of today, the rarity of functionally relevant mutations identified in
familial and/or early onset series does not support the inclusion of BUB1 and BUB3 testing in routine genetic diagnostics
of familial CRC.
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Letter to the editor
Much of the heritability associated with colorectal
cancer (CRC) cannot be explained by the currently
known genetic risk factors for CRC. Genome-wide
genetic and genomic screenings have tried to identify
novel high penetrance genes for CRC. Despite the
identification of novel candidate genes for CRC
predisposition, overall, they account for a very low
number of familial cases, and for many of the suggested
genes, identification of additional mutated families is
essential to conclusively define their actual implication
in CRC predisposition [1].
Based on genome-wide copy number profiling and
exome sequencing in early-onset and familial CRC, De
Voer et al. identified germline mutations in BUB1 and
BUB3, components of the spindle assembly checkpoint
(SAC) and thus controllers of correct chromosome
segregation, as cause for CRC predisposition [2, 3]. Six
germline mutations affecting BUB1 and BUB3 were
identified in 6 independent families. Recently, Broderick
et al. assessed the presence of germline mutations in
proposed genes for CRC predisposition, including BUB1
and BUB3, finding no increased frequency of mutations
in cases compared to controls in either gene [4]. In view
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of the controversial results, the purpose of the present
study is to evaluate the impact, supported by functional
studies, of BUB1 and BUB3 germline variants in the pre-
disposition to CRC and/or polyposis.
Using a strategy that combines pooled DNA amplifica-
tion and massively parallel sequencing, we sequenced
BUB1 and BUB3 in 456 familial colorectal cancer cases (60
Amsterdam-positive families), and in 88 polyposis cases,
without identified mutations in known high-penetrance
genes. Considering novel and rare (population minor allele
frequency (MAF) < 1%) non-synonymous genetic changes,
a total of 4 variants, BUB1 c.1965-1G>A, BUB1
c.2296G>A (p.E766K), BUB1 c.2473C>T (p.P825S) and
BUB3 c.77C>T (p.T26I), were detected in 4 families
(Table 1, Fig. 1). Only BUB1 c.2473C>T was reported in
public databases. Loss of heterozygosity (LOH) causing the
elimination of the wild-type allele or promoter methylation
was not detected in any of the tumors studied (Table 1,
Additional file 1: Table S1), as previously observed [2].
BUB1 c.1965-1G>A, identified in a male patient diag-
nosed with CRC and 25 adenomatous polyps at age 40
with no relevant family history of cancer (Fig. 1), causes
an out-of-frame deletion of 11 bases, produced by the
disruption of the canonical acceptor site of exon 18 and
usage of the next AG as novel splicing acceptor
(r.1965_1975del; p.S655Rfs*32) (Additional file 1: Figure
S1). The EBV-transformed lymphoblastoid cell line ob-
tained from this carrier showed reduced BUB1 mRNA
expression (p = 0.0020) and increased chromosome
segregation errors (p = 0.0050) compared to control
Table 1 Germline genetic variants in BUB1 and BUB3 identified in 544 CRC and/or polyposis families
aMutation [protein domain] BUB1 c.1965-1G>A
(r.1965_1975del; p.S655Rfs*32)
BUB1 c.2296G>A
(p.E766K)
BUB1 c.2473C>T (p.P825S)
[Kinase domain]
BUB3 c.77C>T (p.T26I)
[WD40 repeat 1]
Population MAF (%) (1000G / ESP
/ ExAC/ gnomAD)
n.r. n.r. rs748392521; n.r. / n.r. /
0.004 / 0.005
n.r.
Protein function prediction
(score)
p.S655Rfs*32 bPPH2: PsD (0.934) / N
(0.349)
bPPH2: PrD (1 / 0.997) bPPH2: PsD (0.770 /
0.548)
SIFT: N (0.2) SIFT: D (< 0.0001) SIFT: N (0.06)
Condel: N (0.463) Condel: D (0.542) Condel: D (0.524)
Mut. Taster: D Mut. Taster: D Mut. Taster: D
Align GVGD: N (C0) Align GVGD: D (C65) Align GVGD: N (C0)
Protein stability prediction
(ddG, Kcal/mol)
p.S655Rfs*32 CUPSAT: destabilizing
(−0.69)
CUPSAT: destabilizing
(−1.16)
CUPSAT: destabilizing
(− 0.29)
ERIS: destabilizing (1.57) ERIS: stabilizing (−0.71) ERIS: destabilizing
(1.10)
I-Mutant: destabilizing
(−0.53)
I-Mutant: destabilizing
(−0.64)
I-Mutant: destabilizing
(− 0.68)
PoPMuSIC: destabilizing
(0.04)
PoPMuSIC: stabilizing
(0.17)
PoPMuSIC:
destabilizing (0.33)
Splice site predictions
(Alamut v2.9)
Disrupts acceptor site No change No change No change
RNA study: 11 bp deletion RNA study: no change RNA study: no change
cEvolutionary conservation
(PhyloP / PhastCons)
– 1.239 / 0.95 4.358 / 1 5.572 / 1
Variegated aneuploidy No No n.a. No
Somatic LOH / promoter
methylation
n.a. / n.a. No LOH; No methylation
(II.6 and III.2)
No LOH; No methylation No LOH; n.a.
Functional studies in LCL Damaging effects No effect (incomplete
functional assessment)
n.a. n.a.
d,eVariant classification ePathogenic Likely benign / Uncertain
significance
Uncertain significance Uncertain significance
a. RefSeq GRCh37: BUB1 NM_004336, BUB3 NM_004725
b. Polyphen 2: HumDiv / HumVar scores.
c. PhyloP score (values between -14 and +6): Sites predicted to be conserved are assigned positive scores. PhastCons score (values between 0 and 1): the closer
the value is to 1, the more probable the nucleotide is conserved.
d. According to the standard guidelines for the interpretation of sequence variants (recommendations of the American College of Medical Genetics and Genomics
and the Association for Molecular Pathology) [7].
e. Interpret with caution. BUB1 and BUB3 have not yet been defined as genes with clinical value in hereditary cancer.
Abbreviations: 1000G, 1000 Genomes; bp, base pairs; ca., cancer; D, damaging or deleterious; ESP, NHLBI GO Exome Sequencing Project; ExAC, Exome Aggregation
Consortium; GnomAD, Genome Aggregation Database (http://gnomad.broadinstitute.org); LCL, EBV-transformed lymphoblastoid cell line; N, neutral; n.a., not
available; n.r., not reported; PPH2, polyphen 2; PrD, probably damaging; PsD, possibly damaging
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lymphoblastoid cell lines (Fig. 2a-b). The c.1965-1G>A
cells showed reduced BUB1 levels at the kinetochores,
where the SAC is active, compared to controls (30% re-
duction; p < 0.0001) (Fig. 2c-d).
BUB1 c.2296G>A (p.E766K), located in a β-strand out-
side the protein kinase domain, was identified in three
CRC-affected members of an Amsterdam-positive CRC
family (Fig. 1). Computational analyses predicted a de-
stabilizing effect on the protein (Table 1). However, the
EBV-transformed lymphoblastoid cell line obtained from
the proband did not show reduced BUB1 expression
(Fig. 2a) or reduced BUB1 levels at the kinetochores
(Fig. 2c-d) when compared to controls. Assessment of
chromosome segregation errors could not be performed.
BUB1 c.2473C>T (p.P825S) (rs748392521, MAFExAC:
0.004%), which affects a highly conserved amino acid
(considering 13 species) and is located in the catalytic
kinase domain of the protein, was identified in an
individual diagnosed with CRC at age 44, with no
immediate relatives affected with cancer but with a
cousin diagnosed with CRC at age 44 whose mutation
status could not be assessed (Fig. 1). The variant was
predicted to affect the function and structure of the
protein (Table 1, Fig. 2e and f). Sample unavailability
prevented us from carrying out the specific functional
studies in the patient-derived lymphoblastoid cell line.
Finally, BUB3 c.77C>T (p.T26I) was identified in
patient diagnosed with prostate cancer at age 70 and
two synchronous CRCs and 22 adenomatous polyps at
age 73, belonging to a family fulfilling the Amsterdam I
criteria. The variant, located in the WD40 repeat 1 of a
seven-bladed beta-propeller fold, was predicted to be
functionally deleterious and destabilizing (Table 1). The
location of the mutated residue together with the previ-
ously reported BUB3 CRC-predisposing mutations is
shown in Fig. 2e-f. Co-segregation results in other
cancer-affected family members did not support a causal
role of the variant in the aggregation of cancer in the
Fig. 1 Pedigrees of the families with BUB1 and BUB3 mutations. Filled symbol, cancer. Ages at information gathering or at death (†), when available,
are indicated on the top-right corner, and ages at cancer diagnosis, between brackets after tumor type. Abbreviations: AP, adenomatous polyp; HP,
hyperplastic polyp; JP, juvenile polyp; ca, cancer; CRC, colorectal cancer; PTC, papillary thyroid cancer; N.C., normal colonoscopy; MUT, mutation carrier;
WT (wildtype); non-carrier of the mutation identified in the family
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Fig. 2 (See legend on next page.)
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family (Fig. 1). The in vitro functional studies could not
be performed due to the unsuccessful transformation of
the patient’s lymphocytes.
Cytogenetic analysis of non-transformed lymphocytes
obtained from BUB1 c.1965-1G>A, BUB1 c.2296G>A
(p.E766K), BUB3 c.77C>T (p.T26I) mutation carriers
and from unrelated controls, did not show differences in
the number of metaphases with chromosome number
alterations. Notably, complex chromosomal transloca-
tions were identified in one of 41 metaphases of the
BUB1 c.1965-1G>A carrier, while no chromosomal
translocations were detected in any of the 91 control
metaphases analyzed (Additional file 1: Table S2).
No reminiscent traits of the mosaic variegated aneu-
ploidy syndrome or variegated aneuploidy in lympho-
cytes were found in any of the studied carriers, not even
in the carrier of BUB1 c.1965-1G>A (p.S655Rfs*32).
However, the EBV-transformed lymphocytes from the
latter revealed chromosome segregation errors, which
may lead to aneuploidy in the next cell cycle. It is
unclear what the cell fate of the missegregated cells is,
as the subsequent chromosomal instability might be
detrimental. De Voer et al. identified mosaic aneuploidy
in all three BUB1/BUB3 mutation carriers they studied,
while only two of the three carriers showed dysmorphic
features [2]. On the other hand, no aneuploidies were
observed in a 54 year-old Dupuytren patient without
family history of CRC and a 1.7 Mb deletion of chromo-
some 2q13, which includes BUB1 [5]. These findings
suggest that BUB1/3 monoallelic mutations may or not
cause mosaic aneuploidy and/or phenotypic affectation.
The role of BUB1 and BUB3 in familiar cancer has
been topic of debate in the last years. Recently,
Broderick et al. scrutinized the exomes of 863 familial/
early-onset CRC cases and 1604 cancer-free controls in
order to validate the proposed hereditary CRC genes,
including BUB1 and BUB3 [4]. Neither the herein iden-
tified variants nor the ones identified by De Voer et al.
[2] were detected in the exome study. While only one
novel/rare missense variant predicted to be deleterious
(none stop-gain, frameshift or splice-site variants) was
identified in BUB1 in the 863 cases (0.11%), and none in
BUB3, several (4 in BUB1 (0.25%) and 2 in BUB3
(0.12%)) novel/rare disruptive variants were identified in
controls. Of note, the frequency of disruptive (stop-gain,
frameshift and splice acceptor/donor) mutations in
controls identified by Broderick et al. is remarkably
higher than the frequency of disruptive mutations
annotated in large population-based browsers (BUB1:
ExAC, 0.065% (40 carriers in 60,703 individuals);
GnomAD, 0.063% (88/138,044). BUB3: ExAC, 0.006%
(4/59,569); GnomAD, 0.008% (11/123,084)) [4]. Taking
into account the two largest series analyzed ([4] and
present study), 0.14% (2/1392; 1/863 and 1/529, respect-
ively) of familial and/or early-onset CRC cases would be
explained by functionally relevant germline mutations in
BUB1 (0% in BUB3), compared to a population frequency
of 0.063–0.065%. Nevertheless, despite the demonstrated
functional effect of several BUB1/BUB3 variants, their
causal implication in colorectal carcinogenesis, either
alone or in combination with other mutations/variants in
other genes, is yet to be proven.
To date, 11 CRC families and 1 pancreatic ductal adeno-
carcinoma family with different novel/rare germline muta-
tions in BUB1 or BUB3 have been reported (Additional
file 1: Table S3; Fig. 2e-f) [2, 4, 6]. Of the 12 variants, 7
were proven deleterious based on functional experimental
evidence and/or on their splice-site or frameshift nature,
one did not show any effect, and the remaining 4 missense
variants were not subjected to functional studies. Six of
the 8 mutation carriers (7 families) in whom functionally
relevant mutations have been identified were diagnosed
with CRC at young ages (range: 29–40 years), one of them
together with the presence of 25 adenomas. The increased
risk to other tumor types, such as lung cancer, remains
uncertain until additional functionally relevant mutation
carriers with the disease are identified.
Based on the evidence gathered to date, we conclude that
the paucity of functionally-relevant cancer-predisposing
mutations in BUB1 and BUB3 do not support the need for
germline genetic testing of these genes in familial CRC for
diagnostic purposes.
(See figure on previous page.)
Fig. 2 Functional assays for BUB1 c.1965-1G>A and c.2296G>A (p.E766K) and 3D structure of the proteins and location of the identified BUB1 and
BUB3 germline mutations. a Quantitative analysis of levels of BUB1 mRNA demonstrating reduced BUB1 expression in the c.1965-1G>A cell line
compared to controls. Data are normalized against HPRT expression. Error bars represent standard error mean (SEM) values. b Quantification of
chromosome segregation errors in EBV-transformed cells from a control individual and the BUB1 c.1965-1G>A mutation carrier. Measurements
were performed in triplicate and error bars represent SEM values. c Localization and d quantification of BUB1 levels at the kinetochores of
nocodazole-arrested EBV-transformed cells. Each dot represents one cell and the level of BUB1 is normalized to the kinetochore (KT) intensity of
CENP-C and is the average fold change of three experiments (±SEM) normalized to the values of control cells. Cells from the c.1965-1G>A carrier
revealed reduced levels of BUB1 at the KT in comparison to the control. ** P < 0.001; *** P < 0.0001. e Crystallographic 3D structure of BUB1
(a.a. 736–1083) and location of p.E766K and p.P825S, and 3D model of BUB3 (a.a. 6–324) and location of p.T26I (current study) and p.K21N,
p.R149Q and p.F264L [2]. f Protein domains of BUB1 (UniProtKB - O43683) and BUB3 (UniProtKB - O43684) and location of the identified
mutations. In red, residues affected by mutations identified in this study; in blue, residues affected by the mutations identified by de Voer et al.
[2]; in orange, variants identified by Broderick et al. [4]; and in green, variants detected by Shindo et al. [6]
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